Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRQ3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,980
Award facts
- Contract value 100% obligated
- $13,979.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,979.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Xolair 300 mg/2 ml autoinjector units. The award, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
The PPV-G GEN V represents a $30.3 billion acquisition strategy through which DLA establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across diverse pharmaceutical categories—including biologics, specialty pharmaceuticals, branded and generic prescription medications, and medical supplies—positions it as a critical supplier within the federal military medical supply chain. The company has demonstrated substantial contracting activity with DLA's Medical Supply Chain division, with delivery orders ranging from under $100 to exceeding $115,000, and maintains no identified subcontractor relationships in its federal contract awards.
Quick answers
Who was awarded contract SPE2DR26FCRQ3?
SPE2DR26FCRQ3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FCRQ3 worth?
The government has obligated $13,980 on SPE2DR26FCRQ3.
Is contract SPE2DR26FCRQ3 an order under another contract?
Yes. SPE2DR26FCRQ3 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRQ3 competed?
The extent of competition for SPE2DR26FCRQ3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award